The left atrial appendage (LAA) has been identified as a predominant source of thrombus formation leading to significant thromboembolic events in patients with nonvalvular atrial fibrillation. Medical therapy to eliminate thrombus formation in the LAA has been the standard of care for several decades, but mechanical approaches designed to exclude the LAA from the circulation have recently been developed. The largest body of randomized and nonrandomized data to date has been for the Watchman device (Boston Scientific, Natick, Massachusetts), which was recently approved by the Food and Drug Administration for selected patients in the United States. There are no current guidelines or guidance for institutions and operators looking to become involved in this therapy. This perspective is aimed at exploring these issues and providing necessary information and guidance to these programs and operators to help ensure a successful launch of a LAA occlusion program and optimize patient selection, procedural performance, and outcome. 
Possible clinical scenarios ( Table 1) 1. As an alternative to oral anticoagulation in patients intolerant to oral anticoagulant agents (OACs). Current estimates suggest that up to 40% of people with AF and an indication for OAC have a relative or absolute contraindication to the use of warfarin, and <50% of eligible patients are being treated because of medication intolerance or noncompliance (10) (11) (12) (13) . Whether this pattern of underutilization will be similar with the several new OACs that are now approved is unknown.
These agents have their own unique concerns, such as continued issues with gastrointestinal bleeding, cost, lack of antidotes, and for some of them, the need for twice-a-day dosing. Patients with previous intracranial bleeds, recurrent gastrointestinal bleeds, coagulopathies, and intolerance to NOACs/warfarin will still present clinical challenges. Unfortunately, there is a lack of randomized clinical trial data for use of the LAA occlusion device in these patients. The most robust data available for LAA device occlusion in this group comes from the European PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) study (14) and the ASAP (Aspirin Plavix Feasibility Study with WATCHMAN Left Atrial Appendage Closure Technology) registry (15) . In the ASAP registry, the predicted stroke rate depending on the CHADS 2 score was 7.3% per year and the observed stroke rate was 2.3%. It must be pointed out that these patients were on dual antiplatelet therapy (DAPT) for a duration of approximately 6 months and on aspirin indefinitely thereafter. Potential patients who would be enrolled into this pathway must be able to tolerate short-term DAPT and indefinite use of aspirin. 
